Advances in vaccine delivery: transcutaneous immunisation

Bibliography

• GLENN GM, SCHARTON-KERSTEN T, VASSELL R, MATYASG, ALVING CR: Transcutaneous immunization using bacterial ADP-ribosylating exotoxins as antigens and adjuvants. Infect. Immun. (1999) 67:1100–1106.
   PubMed Web of Science ®Google Scholar
• BIRBECK MS, BREATHNACH AS, EVERALL JD: An electronmicroscope study of basal melanocytes and high level clear cells (Langerhans cells) in vitiligo. J. Invest. Dermatol. (1961) 37:51–55.
   Web of Science ®Google Scholar
• TUTING T, STORKUS WJ, FALO LD, JR.: DNA immuniza-tion targeting the skin: molecular control of adaptive immunity. J. Invest. Dermatol. (1998) 111:183–188.
   Google Scholar
• PALUCKA K, BANCHEREAU J: Dendritic Cells: A linkbetween innate and adaptive immunity. J. Clin. Immunol. (1999) 19:12–25.
   PubMed Web of Science ®Google Scholar
• GLENN GM, SCHARTON-KERSTEN T, VASSELL R, MALLETTCP, HALE TL, ALVING CR: Cutting Edge: Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge. J. Immunol. (1998) 161:3211–3214.
   PubMed Web of Science ®Google Scholar
• SCHARTON-KERSTEN T, GLENN GM, VASSELL R, YU J,WALWENDER D, ALVING CR: Principles of transcuta-neous immunization using cholera toxin as an adjuvant. Vaccine (1999) (In Press).
   Google Scholar
• LIU M: Vaccine developments. Nature Med. (1998) 4 (S5):515–519.
   PubMed Web of Science ®Google Scholar
• THAYAPARAN B, NICOLL A: Prevention and control of tetanus in childhood. Curr. Op. Ped. (1998) 10:4–8.
   PubMedGoogle Scholar
• KATZ SL: Future vaccines and a global perspective. Lancet (1997) 13:1767–1770.
   Web of Science ®Google Scholar
• REIS EC, JACOBSON RM, TARBELL S, WENINGER BG: Taking the sting out of shots: control of vaccination-associated pain and adverse reactions. Ped. Annals (1998) 27:375–386.
   PubMed Web of Science ®Google Scholar
• Reducing the risk of unsafe injections in immuniza-tion programmes, the role of injection equipment. Global programme for vaccines and immunization expanded programme on immunization. WHO. Geneva, Switzerland (1996).
   Google Scholar
• YU RC, ABRAMS DC, ALAIBAC M, CHU AC: Morpho-logical and quantitative analyses of normal epidermal Langerhans cells using confocal scanning laser microscopy. Br. J. Dermatol. (1994) 131(6)843–8.
   Google Scholar
• ELSON CO: Cholera toxin as a mucosal adjuvant. In: Mucosa] Vaccines. Academic Press, New York, USA (1996).
   Google Scholar
• SNIDER DP: The mucosal adjuvant activities of ADP-bacterial enterotoxins. Grit. Rev. Immunol. (1995) 15 (3,4):317–348.
   Google Scholar
• LYCKE N: The mechanism of cholera toxin adjuvan-ticity. Res. Immunol. (1997) 148:504–520.
   PubMedGoogle Scholar
• FREYTAG LC, CLEMENTS JD: Bacterial toxins as mucosaladjuvants. Curr. Top. Microbiol. Immunol. (1999) 236:215–236.
   PubMed Web of Science ®Google Scholar
• MCGHEE JR, KIYONO H, KUBOTA M eta].: Mucosal Thl-versus Th2-type responses for antibody- or cell-mediated immunity to simian immunodeficiency virus in Rhesus macaques. J. Infect. Dis. (1999) 179(S3):480–484.
   Google Scholar
• PORGADOR A, STAATS HF, FAIOLA B, GILBOA E, PALKERTJ: Intranasal immunization with CTL epitope peptides from HIV-1 or ovalbumin and the mucosal adjuvant cholera toxin induces peptide-specific CTLs and protection against tumor development in vivo. J. Immunol. (1997) 158:834–841.
   PubMed Web of Science ®Google Scholar
• ROBERTS MS, WALKER M: Water, the most natural penetration enhancer. In: Pharmaceutical Skin Penetra-tion Enhancement. Walters KA, Hadgraft J (Eds.), Marcel Dekker, New York, USA (1993).
   Google Scholar
• WESTER RC, MAIBACH HI: Penetration enhancement byskin hydration. In: Percutaneous Penetration Enhancers. Smith EW, Maibach HI (Eds.), CRC Press, Boca Raton, USA (1995):21–28.
   Google Scholar
• Fisher's Contact Dermatitis, 4th Edition. Rietschel R1, Fowler JF (Eds.), Williams & Wilkins, Baltimore, MD, USA (1995):2.
   Google Scholar
• BARRY BW: Dermatologic formulations. In: Percuta-neous Absorption. Bronaugh RL, Maibach HI (Eds.), Marcel Dekker, New York, USA:33.
   Google Scholar
• Skin Immune System (SIS), Cutaneous Immunology andClinical Immunodermatology, 2ad Edition. Bos JD (Ed.), CRC Press, Boca Raton, USA (1997).
   Google Scholar
• UDEY MC: Cadherins and Langerhans cell immuno-biology. Clin. Exp. Immunol. (1997) 107(S1):6–8.
   PubMedGoogle Scholar
• KRIPKE ML, MUNN CG, JEEVAN A, TANG JM, BUCANA C: Evidence that cutaneous antigen-presenting cells migrate to regional lymph nodes during contact sensitization. J. Immunol. (1990) 145:2833.
   PubMed Web of Science ®Google Scholar
• ENK AH, KATZ SI: Early molecular events in theinduction phase of contact hypersensitivity. Proc. Nati Acad. Sci. USA (1992) 89:1398.
   PubMed Web of Science ®Google Scholar
• LARRICK JW, MORHENN V, CHIANG YL, SHI T: Activated Langerhans cells release tumor necrosis factor. J. Leukoc. Biol. (1989) 45(5):429–433.
   PubMed Web of Science ®Google Scholar
• JAKOB T, UDEY MC: Langerhans cells: from neurons to nature's adjuvants. In: Advances in Dermatology (1999) 14:209–258.
   PubMedGoogle Scholar
• ENK AH, ANGELONI VL, UDEY MC, KATZ SI: An essentialrole for Langerhans cell-derived IL-1 beta in the initia-tion of primary immune responses in the skin. J. Immunol. (1993) 150:3698.
   PubMed Web of Science ®Google Scholar
• CUMBERBATCH M, KIMBER I: Dermal tumor necrosisfactor-alpha induces dendritic cell migration to lymph nodes and possibly provides one stimulus for Langer-hans cell migration. Immunology (1992) 75:257.32.
   Google Scholar
• MILLER KD, GIBBS RD, MULLIGAN MM, NUTMAN TB, FRANCIS DP: Intradermal hepatitis B virus vaccine: immunogenicity and side effects in adults. Lancet (1983) 2:1454.
   PubMed Web of Science ®Google Scholar
• WHITTLE HC, LAMB WH, RYDER RW: Trials of intrad-ermal hepatitis vaccines in Gambian children. Ann. Trop. Paediatr. (1987) 7:6–9.
   PubMed Web of Science ®Google Scholar
• BOULOC A, WALKER P, GRIVEL JC, VOGEL JC, KATZ SI:Immunization through dermal delivery of protein-encoding DNA: A role for migratory dendritic cells. Eur. J. Immunol. (1999) 29:446–454.
   PubMed Web of Science ®Google Scholar
• MACATONIA SE, KNIGHT SC, EDWARDS AJ, GRIFFITHS S,FRYER P: Localization of antigen on lymph node dendritic cells after exposure to the contact sensitizer fluorescein isothiocyanate. Functional and morpho-logical studies. J. Exp. Med. (1987) 166(6):1654–67.
   Google Scholar
• HOLMGREN J, SVENNERHOLM AM: Mechanisms of disease and immunity in cholera: a review. J. Infect. Dis. (1977) 136 (Suppl.) :105–112.
   Google Scholar
• RUSSELL MW, WU HY, HAJISHENGALLIS G, HOLLINGSHEAD SK, MICHALEK SM: Cholera toxin B subunit as an immunomodulator for mucosal vaccine delivery. Adv. Vet. Med. (1999) 41:105–114.
   PubMedGoogle Scholar
• BLANCHARD TG, LYCKE N, CZINN SJ, NEDRUD JG: Recombinant cholera toxin B subunit is not an effective mucosal adjuvant for oral immunization of mice against Helicobacter. Immunology (1998) 94:22–27.
   PubMed Web of Science ®Google Scholar
• DICKINSON BL, CLEMENS JD: Dissociation of Escheri-chia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect. Immun. (1995) 63:1617–1623.
   PubMed Web of Science ®Google Scholar
• GIULIANI MM, DEL GIUDICE G, GIANNELLI V et al.:Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity. J. Exp. Med. (1998) 187:1123–1132.
   PubMed Web of Science ®Google Scholar